Portfolio

Prism BioLab

PRISM BioLab focuses on developing technology for proprietary small molecule drug discovery for undruggable targets. PRISM BioLab established a Library designed to mimic α-helix or β-turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation.

prismbiolab.com

Deuteroncology

DeuterOncology is focused on the pre-clinical validation and development of DO-2, a novel MET and RAS pathway inhibitor sublicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. DeuterOncology’s portfolio contains a sublicense to the all OCTIMET compounds, includes a clinical-stage MET kinase inhibitor that has been evaluated in both a monotherapy and combination therapy setting in cancer patients in Europe. DeuterOncology works together with a broad established network of collaborators across the world to try to bring new solutions to cancer patients

deuteroncology.com

J-Pharma

Established in December of 2005, J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.

j-pharma.com/en/

Metabolys

Metabolys is developing a small molecule to treat patients suffering from metabolic diseases, especially Non Alcoholic Steato-Hepatitis (NASH). This small molecule (MTBL0036) targets the mitochondrial pyruvate carrier (MPC). Pyruvate lies at a central biochemical node connecting carbohydrate, amino acid, and fatty acid metabolism, and the regulation of pyruvate flux into mitochondria represents a critical step in intermediary metabolism impacting numerous diseases. With the first preclinical data generated by the company, the MTBL0036 seems to be the most efficient of all the orally active anti-NASH and antifibrotic candidates in development when assessed with the STAM animal model of NASH. Easy to produce, it seems to be very efficacious for inhibiting both inflammation and liver cell destruction and could potentially be used complementary of other anti-NASH candidates.

metabolys.com/

Chromacure

Chromacure is seeking to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company will develop inhibitors of a novel target that is a key regulator of tumor initiation and progression.

chromacure.com

Epics therapeutics

EPICS THERAPEUTICS is developing first-in-class drugs in oncology based on RNA epigenetics. The company focuses on discovery and development of small molecule inhibitors of RNA-modifying enzymes to treat cancer.

epicstherapeutics.com